Phenibut, a calming drug prescribed in Russia for anxiety, insomnia, fatigue and dizziness and sold online for calm and focus, has modest support from studies lacking placebo or healthy adults; aging effects are unknown. Tolerance can develop within weeks, stopping heavy daily use can bring severe withdrawal, and overdoses, especially with alcohol or sedatives, can cause coma. Brief, low-dose, infrequent pharmaceutical use sits at the lower end of documented risk. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT | 7–56 U/L | Safety check: rising values stop use |
| AST | 10–40 U/L | Safety check: rising values stop use |
| Complete blood count with differential | Hemoglobin 13.5–17.5 g/dL men, 12.0–15.5 g/dL women; white cells 4.5–11.0 × 10⁹/L | Safety check: abnormal counts stop use |
| Serum creatinine | 0.7–1.3 mg/dL men, 0.6–1.1 mg/dL women | Safety check: impaired clearance changes dose |
Cadence: Baseline liver function, blood count and kidney function before a course; liver enzymes and blood count at 4 weeks, then every 1–3 months while use continues; kidney function every 3–6 months; symptom ratings weekly during the first month, then monthly.